Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone demethylase UTY is a Y-chromosome-encoded enzyme in humans responsible for catalyzing the demethylation of trimethylated lysine 27 on histone H3 (H3K27me3), although it has significantly lower catalytic activity compared to its X chromosome homolog KDM6A (UTX)[4][5]. UTY contains tetratricopeptide repeat domains implicated in protein–protein interactions and plays a role in chromatin organization and epigenetic gene regulation. It is male-specific and also functions as a minor histocompatibility antigen, which can trigger immune responses leading to graft rejection in male-to-female stem cell transplantation[3]. While it is enzymatically active in vitro, its activity is lower and possibly more target-selective in cells compared to KDM6A[4][5]. Emerging studies indicate UTY may also contribute to gene regulation via demethylase-independent mechanisms[1]. Its dysfunction or misregulation has been implicated in developmental anomalies and cancer, and its antigenicity is clinically notable in transplantation settings[1][3][4].
Inhibition of UTY would be expected to increase histone H3K27 methylation, promoting transcriptional repression at specific loci[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone demethylase UTY (UTY).